Intercept Pharmaceuticals Inc. reported $30.4 million in second-quarter global net sales of Ocaliva (obeticholic acid, or OCA), beating consensus estimates of $26 million to $27 million. Moreover, the phase II AESOP trial of OCA in individuals with primary sclerosing cholangitis (PSC) met its primary endpoint of statistically significant reduction in alkaline phosphatase (ALP), an accepted biomarker, while the phase II CONTROL trial also met its objective, confirming statin co-administration with OCA reduces LDL to levels below baseline in patients with nonalcoholic steatohepatitis (NASH).